Insights - Sarilumab, a new Rheumatoid Arthritis (RA) drug from Sanofi (SNY) and Regeneron (REGN), showed positive results in its first Phase 3 clinical trial. If approved, … Continue Reading
Read nowInsights - Forest Laboratories Inc. (FRX) and Gedeon Richter Plc. announced that the U.S. Federal Drug Administration (FDA) issued a complete response letter regarding the New Drug … Continue Reading
Read nowInsights - Amgen’s (AMGN) PCSK9 inhibitor evolucumab (AMG145), when added to standard treatments, helped 86% of patients get their LDL cholesterol levels to a target of 100 … Continue Reading
Read nowInsights - It appears that Vertex Pharmaceutical’s (VRTX) decision to scale back its support for its Hepatitis-C treatment, Incivek, was well reasoned in the face of continued … Continue Reading
PremiumInsights - Amgen’s (AMGN) melanoma treatment, talimogene laherparepvec, showed a four-month longer interim overall survival in a phase 3 trial versus granulocyte-macrophage colony-stimulating factor (GM-CSF). Amgen (AMGN) … Continue Reading
Read nowInsights - There’s nothing worse for an acquirer than finding out that what they are buying is not what it seems. Good news for Endo Health (ENDP) … Continue Reading
Read nowInsights - In a victory for generic-drug makers, late Wednesday, U.S. Supreme Court Chief Justice John Roberts refused to block a ruling that would temporarily stop the … Continue Reading
Read now
